No major benefit in adding mirtazapine for depression in primary care practices

Abstract

Adding mirtazapine to a selective serotonin reuptake inhibitor (SSRI) or serotonin‐norepinephrine reuptake inhibitor (SNRI) for the treatment of treatment‐resistant depression did not significantly improve depressive symptoms over placebo in a trial involving 480 adults recruited from primary care practices. Adverse events were more common in the mirtazapine group and led to a high number of discontinuations from treatment, the researchers reported. Study results were published online Oct. 31 in the BMJ.